___

1. de Matos EG, Hannemann TV, Atzendorf J, Kraus L, Piontek D. The consumption of new psychoactive substances and methamphetamine. Dtsch Arztebl Int 2018; 115:49-55.

2. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2012. United Nations; Vienna: 2013.

3. European Monitoring Centre for Drugs and Drug Addiction. Exploring methamphetamine trends in Europe, EMCDDA Papers, Publications Office of the European Union, Luxembourg, 2014. http://www.emcdda.europa.eu/system/ files/publications/787/TDAU14001ENN_460800.pdf (Last accessed on 13 March 2018)

4. Vearrier D, Greenberg MI, Miller SN, Okaneku JT, Haggerty DA. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Dis Mon 2012; 58:38-89. [CrossRef]

5. Shrem MT, Halkitis PN. Methamphetamine abuse in the United States: contextual, psychological and sociological considerations. J Health Psychol 2008; 13:669-679. [CrossRef]

6. Ahmad K. Asia grapples with spreading amphetamine abuse. Lancet 2003; 361:1878-1879. [CrossRef]

7. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Substance Abuse and Mental Health Services Administration; Rockville, MD: 2013.

8. Karakukcu C, Ciraci MZ, Kocer D, Erturk-Zararsiz G, Reyhancan M, Altintop I. Regional drug abuse prevalence depending on laboratory based urine illicit drug screening results. Anadolu Psikiyatri Derg 2018; 19:169-176. [CrossRef]

9. Gouzoulis-Mayfrank E, Härtel-Petri R, Hamdorf W, HavemannReinecke U, Mühlig S, Wodarz N. Methamphetamine-related disorders. Dtsch Arztebl Int 2017; 114:455-641.

10. Kirby T, Thornber-Dunwell M. High-risk drug practices tighten grip on London gay scene. Lancet 2013; 381:101-102. [CrossRef]

11. Radfar SR, Mohsenifar S, Noroozi A. Integration of methamphetamine harm reduction into opioid harm reduction services in Iran: preliminary results of a pilot study. Iran J Psychiatry Behav Sci 2017; 11:e7730. [CrossRef]

12. Massah O, Moradi A. The prevalence of methamphetamine dependence among Iranian women in methadone maintenance therapy in Tehran, Iran. Iranian Journal of Psychiatry 2018; 13:10-14.

13. Alammehrjerdi Z, Ezard N, Dolan K. Methamphetamine dependence in methadone treatment services in Iran: the first literature review of a new health concern. Asian J Psychiatr 2018; 31:49-55. [CrossRef]

14. Ciccarone D. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care 2011; 38:41-58. [CrossRef]

15. Mendelson J, Uemura N, Harris D, Nath RP, Fernandez E, Jacob P 3rd, Everhart ET, Jones RT. Human pharmacology of the methamphetamine stereoisomers. Clin Pharmacol Ther 2006; 80:403-420. [CrossRef]

16. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2013. United Nations; Vienna: 2013.

17. Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend 2014; 143:11-21. [CrossRef]

18. Chomchai C, Chomchai S. Global patterns of methamphetamine use. Curr Opin Psychiatry 2015; 28:269-274. [CrossRef]

19. McKetin R, Kozel N, Douglas J, Ali R, Vicknasingam B, Lund J, Li JH. The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev 2008; 27:220-228. [CrossRef]

20. Degenhardt L, Roxburgh A, Black E, Bruno R, Campbell G, Kinner S, Fetherston J. The epidemiology of methamphetamine use and harm in Australia. Drug Alcohol Rev 2008; 27:243-252. [CrossRef]

21. Topp L, Degenhardt L, Kaye S, Darke S. The emergence of potent forms of methamphetamine in Sydney, Australia: a case study of the IDRS as a strategic early warning system. Drug Alcohol Rev 2002; 21:341-348. [CrossRef]

22. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci 2003; 15:317-325. [CrossRef]

23. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009; 104:1085-1099. [CrossRef]

24. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005; 75:406-433. [CrossRef]

25. Yamamoto BK, Moszczynska A, Gudelsky GA. Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci 2010; 1187:101-121. [CrossRef]

26. Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008; 27:253-262. [CrossRef]

27. Baumann MH, Ayestas MA, Sharpe LG, Lewis DB, Rice KC, Rothman RB. Persistent antagonism of methamphetamineinduced dopamine release in rats pretreated with GBR12909 decanoate. J Pharmacol Exp Ther 2002; 301:1190-1197. [CrossRef]

28. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995; 18:22-29. [CrossRef]

29. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 2005; 13:141-154. [CrossRef]

30. Kim I, Oyler JM, Moolchan ET, Cone EJ, Huestis MA. Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Ther Drug Monit 2004; 26:664-672. [CrossRef]

31. Oyler JM, Cone EJ, Joseph RE Jr, Moolchan ET, Huestis MA. Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans. Clin Chem 2002; 48:1703-1714.

32. Wallace TL, Gudelsky GA, Vorhees CV. Methamphetamineinduced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci 1999; 19:9141-9148.

33. Moszczynska A, Callan SP. Molecular, behavioral, and physiological consequences of methamphetamine neurotoxicity: implications for treatment. J Pharmacol Exp Ther 2017; 362:474- 488. [CrossRef]

34. Pike E, Stoops WW, Rush CR. Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine. Pharmacol Biochem Behav 2016; 150-151:87-93. [CrossRef]

35. Rusyniak DE. Neurologic manifestations of chronic methamphetamine abuse. Neurol Clin 2011; 29:641-655. [CrossRef]

36. Hart CL, Gunderson EW, Perez A, Kirkpatrick MG, Thurmond A, Comer SD, Foltin RW. Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 2008; 33:1847-1855. [CrossRef]

37. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, Iguchi M; Methamphetamine Treatment Project. Psychiatric symptoms in methamphetamine users. Am J Addict 2004; 13:181-190. [CrossRef]

38. Harro J. Neuropsychiatric adverse effects of amphetamine and methamphetamine. Int Rev Neurobiol 2015; 120:179-204. [CrossRef]

39. Richards JR, Bretz SW, Johnson EB, Turnipseed SD, Brofeldt BT, Derlet RW. Methamphetamine abuse and emergency department utilization. West J Med 1999; 170:198-202.

40. Richards JR, Johnson EB, Stark RW, Derlet RW. Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med 1999; 17:681-685. [CrossRef]

41. Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict 2004; 13:248-255. [CrossRef]

42. Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G, Rawson R, London ED. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 2010; 105:1809-1818. [CrossRef]

43. Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, Carlo G, Bevins RA. Methamphetamineassociated psychosis. J Neuroimmune Pharmacol 2012; 7:113- 139. [CrossRef]

44. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 2004; 1025:279- 287. [CrossRef]

45. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Diagnostic Criteria For Research; Geneva: 1992.

46. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5. Arlington, VA: American Psychiatric Publishing; 2013.

47. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs 2014; 28:1115- 1126. [CrossRef]

48. Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, Thummawomg P, Dumrongchai U, Chutha W. Longterm outcomes in methamphetamine psychosis after first hospitalization. Drug Alcohol Rev 2010; 29:456-461. [CrossRef]

49. Shin EJ, Dang DK, Tran TV, Tran HQ, Jeong JH, Nah SY, Jang CG, Yamada K, Nabeshima T, Kim HC. Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. Arch Pharm Res 2017; 40:403-428. [CrossRef]

50. Potvin S, Pelletier J, Grot S, Hébert C, Barr AM, Lecomte T. Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis. Addict Behav 2018; 80:154-160. [CrossRef]

51. Dean AC, Groman SM, Morales AM, London ED. An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology 2013; 38:259- 274. [CrossRef]

52. Iudicello JE, Woods SP, Vigil O, Scott JC, Cherner M, Heaton RK, Atkinson JH, Grant I; HIV Neurobehavioral Research Center (HNRC) Group. Longer term improvement invneurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. J Clin Exp Neuropsychol 2010; 32:704-718. [CrossRef]

53. Kalechstein AD, Newton TF, Longshore D, Anglin MD, van Gorp WG, Gawin FH. Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci 2000; 12:480-484. [CrossRef]

54. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 2007; 17:275-297. [CrossRef]

55. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R; Methamphetamine Treatment Project. Risk factors for suicide attempts in methamphetamine-dependent patients. Am J Addict 2008; 17:24-27. [CrossRef]

56. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 2010; 69:578-592. [CrossRef]

57. Härtel-Petri R, Krampe-Scheidler A, Braunwarth WD, Havemann-Reinecke U, Jeschke P, Looser W, Mühlig S, Schäfer I, Scherbaum N, Bothe L, Schaefer C, Hamdorf W. Evidence-based guidelines for the pharmacologic management of methamphetamine dependence, relapse prevention, chronic methamphetamine-related, and comorbid psychiatric disorders in post-acute settings. Pharmacopsychiatry 2017; 50:96-104. [CrossRef]

58. Bhatt M, Zielinski L, Baker-Beal L, Bhatnagar N, Mouravska N, Laplante P, Worster A, Thabane L, Samaan Z. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis. Syst Rev 2016; 5:189. [CrossRef]

59. Ballester J, Valentine G, Sofuoglu M. Pharmacological treatments for methamphetamine addiction: current status and future directions. Expert Rev Clin Pharmacol 2017; 10:305-314.

60. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 2008; 27:309-317. [CrossRef]

61. McElhiney MC, Rabkin JG, Rabkin R, Nunes EV. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study. Am J Drug Alcohol Abuse 2009; 35:34-37. [CrossRef]

62. Reback CJ, Shoptaw S. Development of an evidence-based, gay-specific cognitive behavioral therapy intervention for methamphetamine-abusing gay and bisexual men. Addict Behav 2014; 39:1286-1291. [CrossRef]

63. Roll JM, Chudzynski J, Cameron JM, Howell DN, McPherson S. Duration effects in contingency management treatment of methamphetamine disorders. Addict Behav 2013; 38:2455- 2462. [CrossRef]

64. Baicy K, London ED. Corticolimbic dysregulation and chronic methamphetamine abuse. Addiction 2007; 102(Suppl 1):5-15. [CrossRef]

65. Morris L, Stander J, Ebrahim W, Eksteen S, Meaden OA, Ras A, Wessels A. Effect of exercise versus cognitive behavioural therapy or no intervention on anxiety, depression, fitness and quality of life in adults with previous methamphetamine dependency: a systematic review. Addict Sci Clin Pract 2018; 13:4. [CrossRef]

66. Rostami R, Dehghani-Arani F. Neurofeedback training as a new method in treatment of crystal methamphetamine dependent patients: a preliminary study. Appl Psychophysiol Biofeedback 2015; 40:151-161. [CrossRef]

67. Mravcik V, Skarupova K, Orlikova B, Zabransky T, Karachaliou K, Schulte B. Use of gelatine capsules for application of methamphetamine: a new harm reduction approach. Int J Drug Policy 2011; 22:172-173. [CrossRef]